Phase 3 Readout

AXIM: Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera

Name: Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera
Start: 2028-07-01
End: 2028-07-01

July 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: July 1, 2028
Company: AXIM BIOTECHNOLOGIES, INC. (AXIM)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera

July 1, 2028

AXIM overview →

Company: AXIM BIOTECHNOLOGIES, INC. (AXIM)
Indication: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1